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Background: The role of plasma monoamines in patients with chronic obstructive pulmonary disease (COPD) with
depression is unclear. To investigate monoamines in 20 depressed patients with COPD, the plasma concentrations
of serotonin, 5-hydroxyindoleacetic acid (5-HIAA), homovanillic acid, and 3-methoxy-4-hydroxyphenylglycol (MHPG)
were measured and compared with those in 50 non-depressed COPD patients, and also with 23 age- and
gender-matched non-smokers and 13 smokers as non-depressed healthy controls.
Methods: Diagnosis of depression was assessed using the Centre for Epidemiologic Studies Depression Scale.
Plasma concentrations of monoamines were measured by high-performance liquid chromatography.
Results: None of the depressed COPD patients had suicidal ideation. The plasma 5-HIAA level [median, (25% and
75% quartiles)] in depressed COPD patients [6.8 ng/mL, (4.9 and 13.1)] was significantly higher than in
non-depressed COPD patients [5.4, (4.2 and 7.5)] (p=0.022) and non-smokers [5.1 (3.8 and 7.2)] (p=0.041), but not
smokers [4.7, (4.0 and 6.7)] (p>0.05). The plasma 5-HIAA level (r=0.24, p=0.049) was significantly associated with the
severity of depression in patients with COPD. The plasma MHPG level was significantly higher in depressed COPD
patients (p=0.043) than in smokers, but was not higher than that in non-depressed COPD patients or non-smokers,
although the level of MHPG was not associated with the severity of depression.
Conclusion: The plasma 5-HIAA level is increased in depressed COPD patients. Plasma monoamines may be a
good biomarker for detection of depression in patients with COPD.
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Chronic obstructive pulmonary disease (COPD) is
characterized by a chronic airflow limitation, and is
recognized as a major health problem responsible
for chronic morbidity and mortality worldwide [1].
Symptomatic COPD patients who have suffered pre-
vious repeated exacerbations have poor disease con-
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distribution, and reproduction in any mediumand prevention of exacerbations may contribute to
an improvement of health-related quality of life
(HRQOL) and lower mortality for patients with COPD.
COPD patients often have psychological disorders,
including depression, and such patients tend to have
more frequent exacerbations and a poor prognosis
[3-7]. Recently, we demonstrated that depressed
COPD patients had a lower HRQOL and more fre-
quent exacerbations and hospitalizations those non-
depressed COPD patients [3]. The severity of depres-
sion in COPD is closely associated with suicidal
ideation [8,9].ed Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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ated with dysfunction of brain monoaminergic neurons,
and that the levels of serotonin (5-hydroxytryptamine
[5-HT]) released in the brain are linked to a decrease
in responsiveness to anti-depressants [10,11]. It is also
well known that the functions of monoamine and
monoamine oxidase are associated with smoking-related
diseases [12,13]. However, the relationship between levels
of plasma monoamines and their metabolites in patients
with COPD-associated depression is still unclear.
In the present study, we analyzed serotonin metabo-
lites to investigate possible biomarkers of depressed
COPD patients. Plasma homovanillic acid (HVA), 3-
methoxy-4-hydroxyphenylglycol (MHPG), 5-HT, and 5-
hydroxyindoleacetic acid (5-HIAA) were measured in
COPD patients who were depressed (depressed COPD)
and COPD patients who were not depressed (non-de-
pressed COPD), and also in age- and gender-matched
non-depressed nonsmokers and smokers as controls.Methods
Participants
The subjects of this study were outpatients or healthy
volunteers. We randomly enrolled 70 patients with COPD,
and recruited 36 age- and gender-matched healthy con-
trols between September 1st 2009 and August 31st 2011 at
the Chest Disease Center of Kurume University Hospital,
Japan (Table 1). All of the patients analyzed had had stable
COPD for at least 4 weeks prior to blood tests. None had
received oral or injective corticosteroids or antibiotics for
4 weeks prior to the blood tests. Individuals with asthma,
bronchiectasis, interstitial pneumonia, tuberculosis, pneu-
moconiosis, ischemic heart disease, chronic heart disease,
renal or liver failure, active malignancies of any organs,
sleep apnea syndrome, and a presence and history of psy-
chological diseases such as major depression, bipolar dis-
order, or schizophrenia were excluded. Also excluded were
patients who had been taking anti-depressants, and pa-
tients who had a history of lung volume reduction surgery,
lung transplantation, or pneumonectomy. Patients with
central nervous system disorders and cerebrovascular dis-
eases were excluded on the basis of brain computed tom-
ography (CT) or magnetic resonance imaging (MRI)
examinations. Patients with COPD who were undertaking
respiratory rehabilitation, or receiving long-term oxygen
therapy and non-invasive positive pressure ventilation
were excluded, because these treatments are thought to
affect psychological status. We carefully excluded any sub-
jects with renal function disorders (serum creatinine levels
>1.2 mg/dL).
As reported previously [14,15], the sample sizes for the
patients with COPD and healthy controls were >70 and
>35, respectively, in plasma levels of monoamines, whenthe sample ratio was 1:2 (power = 80%; alpha error = 5%;
and beta error = 80%).
Study protocol
After the patients had provided written informed consent,
information on age, gender, smoking status (current-, ex-
or non-smoker), cumulative smoking history (pack-yrs),
body mass index (BMI; weight/height2), comorbidities,
and history of pharmacological treatments was obtained.
Each subject underwent blood tests, spirometry, electro-
cardiography, chest radiography, chest high-resolution CT
(HRCT), and brain CT or MRI. Spirometry and broncho-
dilator response tests were performed using an electronic
spirometer (Chestgraph Jr HI-101, CHEST Ltd., Tokyo,
Japan) in accordance with the American Thoracic Society
(ATS) recommendations [16]. A metered-dose salbutamol
(400 mcg/subject, GSK, Japan) inhaler was used as a bron-
chodilator, and bronchodilator response tests were per-
formed before and 30 min after salbutamol inhalation.
Predicted values of spirometry parameters were calculated
according to the prediction equations of the Japanese
Respiratory Society, as we have reported previously [17].
HRQOL was assessed using the validated Japanese St.
George’s Respiratory Questionnaire (SGRQ) [18,19]. The
SGRQ contains three subscales (symptoms, activity, and
impact), and the total score varies from 0 to 100 with a
higher score indicating a worse health status [19]. Dyspnea
was evaluated using the 5-grade (0 to 4) modified Medical
Research Council (mMRC) dyspnea scale [20]. Arterial
blood gas analysis was performed with each subject supine
breathing room air. After assessing the SGRQ, the mMRC
dyspnea scale, and the Centre for Epidemiologic Studies
depression (CES-D) scale (Purchased from Saccess Bell
Co., Ltd, Japan) for depression, all blood samples were
taken between 9:00 and 10:00 AM following 10 minutes
with the subjects supine. Samples were kept at -80°C until
analysis.
The study protocols (Approval No. 08091, May 29th,
2009) were approved by the research ethics board of
Kurume University and written informed consent was
obtained from the internal review board and all
participants.
Diagnosis and severity of COPD
Diagnosis and staging of COPD were in accordance with
the Global Initiative for Chronic Obstructive Lung
Disease (GOLD) guidelines [2], and included a post-
bronchodilator forced expiratory volume in 1 second/
forced vital capacity (FEV1/FVC) ratio of <70%, and
<200 mL and <12% reversibility of FEV1 before and after
bronchodilator administration. Patients with COPD who
had a smoking history of 10 pack-yrs and over and also
had emphysematous changes in the lungs were selected
to carefully remove asthmatics. The emphysematous
Table 1 Profiles of the four participant groups
Parameter Control subjects COPD patients
Nonsmokers Smokers Non-depressed Depressed
Number of subjects 23 13 50 20
Age (yr) 66.7 ± 9.0 66.5 ± 11.6 68.5 ± 7.2 68.2 ± 7.8
Gendera (no. of males; %) 15 (65.2) 12 (92.3) 47 (94.0) 14 (70.0)
Body mass index (kg/m2) 22.1 ± 2.4 23.0 ± 2.8 21.9 ± 3.1 19.8 ± 3.8†
Smoking statusa
Non / Ex / Cu (no.) 23 / 0 / 0 0 / 4 / 9 0 / 33 / 17 0 / 14 / 6
Smoke index (pack-yrs) 0 40.0 ± 18.2*** 59.3 ± 30.3*** 52.2 ± 27.0***
Comorbiditiesa
Hypertension (no; %) 7 (30.4) 4 (30.8) 13 (26.0) 4 (20.0)
Diabetes (no; %) 5 (21.7) 1 (7.7) 11 (22.0) 6 (30.0)
Duration of COPD (yr) N/A N/A 5.3 ± 3.9 5.5 ± 4.4
GOLD stagea
I / II / III / IV (no.) N/A N/A 7 / 22 / 17 / 4 2 / 4 / 8 / 6
Lung function parameters
Before bronchodilator
FVC (L) 3.5 ± 0.9 3.6 ± 0.7 3.4 ± 0.8 2.7 ± 0.9*†‡
%FVC 108.5 ± 17.0 105.6 ± 19.3 98.8 ± 18.3 86.4 ± 22.2**†
FEV1 (L) 2.6 ± 0.6 2.6 ± 0.5 1.5 ± 0.6
***††† 1.1 ± 0.7***†††
%FEV1 100.8 ± 14.3 94.9 ± 20.1 54.9 ± 20.8
***††† 44.8 ± 24.9***†††
FEV1/FVC (%) 77.2 ± 6.9 73.8 ± 5.2 44.4 ± 12.7
***††† 41.0 ± 16.2***†††
After bronchodilator
FVC (L) 3.4 ± 0.9 3.5 ± 0.7 3.4 ± 0.8 2.6 ± 1.0*†‡
%FVC 108.0 ± 17.4 104.3 ± 18.0 99.3 ± 18.5 84.9 ± 23.5**†‡
FEV1 (L) 2.7 ± 0.6 2.7 ± 0.4 1.6 ± 0.6
***††† 1.2 ± 0.7***†††
%FEV1 103.0 ± 15.5 96.5 ± 19.9 56.4 ± 20.8
***††† 45.3 ± 25.0***†††
FEV1 / FVC (%) 79.2 ± 6.5 76.0 ± 5.9 45.6 ± 13.4
***††† 42.3 ± 15.9***†††
Reversibility of FEV1 (%) 2.2 ± 4.5 1.8 ± 3.8 3.3 ± 5.3 1.0 ± 5.2
Arterial blood gases
PaO2 (Torr) 90.3 ± 7.5 92.9 ± 5.9 76.6 ± 9.5
***††† 71.9 ± 13.9***†††
PaCO2 (Torr) 41.4 ± 3.2 41.7 ± 3.5 40.0 ± 4.0 44.6 ± 7.1
‡
mMRC dyspnea scale 0.0 ± 0.0 0.2 ± 0.6 1.0 ± 1.1***††† 2.1 ± 1.6***†††§
SGRQ
Total score (units) 8.4 ± 8.3 15.7 ± 12.0 32.6 ± 15.9***†† 57.8 ± 20.8***†††¶
Symptom score (units) 19.6 ± 13.4 30.9 ± 18.9 40.8 ± 21.3**†† 66.2 ± 16.7***†††¶
Activity score (units) 6.0 ± 7.1 20.9 ± 17.2 42.9 ± 24.1***††† 68.2 ± 29.7***†††§
Impact score (units) 6.2 ± 10.0 8.0 ± 9.9 21.3 ± 13.9**†† 52.0 ± 23.2***†††¶
CES-D scale 1.7 ± 2.9 2.5 ± 3.1 8.5 ± 5.2***††† 24.5 ± 6.0***†††¶
Treatments for COPDb
LAMA (no; %) 0 0 33 (66.0) 16 (80.0)
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Table 1 Profiles of the four participant groups (Continued)
LABA (no; %) 0 0 21 (42.0) 10 (50.0)
ICS (no; %) 0 0 15 (30.0) 11 (55.5)
SRT (no; %) 0 0 7 (14.0) 4 (20.0)
All data were expressed as mean ± SD and compared by one-way ANOVA and Tukey-Kramer test for multiple comparisons among the four groups.
a Data were compared among groups by chi-squared test for trend.
b Data were compared between depressed and non-depressed COPD patients by Fisher’s exact test. Numbers of non-depressive and depressive COPD patients
who used salmeterol and fluticasone devices in combination were 13 and 10, respectively. Some patients were taking multiple medications.
* p<0.05, ** p<0.01, and *** p<0.001 vs. nonsmokers.
† p<0.05, †† p<0.01, and ††† p<0.001 vs. smokers.
‡ p<0.05, § p<0.01, and ¶ p<0.001 vs. non-depressed COPD patients.
Non, non-smokers; Ex, ex-smokers; Cu, current smokers; GOLD, Global Initiative for Chronic Obstructive Lung Disease; FVC, forced expiratory capacity; FEV1, forced
expiratory volume in 1 second; PaO2, partial pressure of arterial oxygen; PaCO2, partial pressure of arterial carbon dioxide; mMRC, modified Medical Research
Council; SGRQ, St George’s respiratory questionnaire; CES-D, Center for Epidemiological Studies depression scale; LAMA, long-acting muscarinic receptor
antagonist; LABA, long-acting β2 agonist; ICS, inhaled corticosteroid; SRT, slow-release theophylline; N/A, not available.
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areas by chest HRCT [21].
Diagnosis of depression
Diagnosis of depression was assessed using the validated
Japanese CES-D scale. The cut-off point for depression
was CES-D >16 [22,23] and a CES-D score was assessed
for each subject. The results of the CES-D score were
not opened until this study was completed. Therefore,
physicians did not know the psychological conditions of
each subject. In this study, patients with a CES-D score
of > 16 were a subgroup of “depressed” COPD patients.
For the purpose of this study, “depression” means pos-
sible “depression” as determined by the CES-D score.
Measurement of plasma monoamine levels
Plasma levels of 5-HT, 5-HIAA, HVA, and MHPG were
measured by high-performance liquid chromatography
(SRL Inc., Tokyo, Japan), as previously reported [15,24-26].
The lowest detection limits for 5-HT, 5-HIAA, HVA, and
MHPG were 0.01 μg/mL, 1.8 ng/mL, 4.4 ng/mL, and
3.2 ng/mL, respectively, and for statistical analysis one half
of the lowest value was assigned if the value was below the
detection limit.
Statistical analyses
Data analyses were performed using JMP version 7 (SAS
Institute, Inc., Cary, NC). Data for the subjects were
expressed as the mean ± standard deviation (SD), and
data for plasma monoamine levels were expressed as the
median, and 25% and 75% quartiles. Statistical analyses
were performed using parametric Student’s t test for
comparison between two groups, or one-way analysis of
variance (ANOVA) and Tukey-Kramer test for multiple
comparisons among four groups. Correlations were ana-
lyzed by parametric or non-parametric Spearman’s tests.
Differences between groups were evaluated using the
chi-squared test for trend and Fisher’s exact test. The
level of significance was set at P <0.05.Results
Subject characteristics
A total of 106 subjects participated in the study and the
characteristics of the four groups, namely the 23 non-
smokers and 13 smokers (as age- and gender-matched
non-depressed healthy controls), and 50 non-depressed
and 20 depressed COPD patients, are compared in Table 1.
The depressed subjects without COPD were not enrolled
in the study. None of participants, including the depressed
COPD patients, had any history of attempted suicide.
The control subjects were 23 non-, 4 Ex-, and 9
current smokers, whereas the number of non-, Ex-, and
current smokers were zero, 57, and 23 in patients with
COPD (p<0.001). There was no significant difference in
the smoke index among smokers, and non-depressed,
and depressed COPD patients. There were no significant
difference in the populations of subjects with hyperten-
sion and diabetes among nonsmokers, smokers, and,
non-depressed, and depressed COPD patients (p>0.05).
All the subjects with hypertension had been taking anti-
hypertensive medications whereas the numbers of non-
smokers, smokers, non-depressed, and depressed COPD
patients taking anti-diabetes medications were 5, 1, 7
and 4, respectively.
In COPD, there was no significantly difference in dur-
ation of COPD between non-depressed and depressed
COPD patients (p>0.05). The depressed COPD patients
trended to have more progressive GOLD stages than the
non-depressed patients but there was no significant differ-
ence in the populations of GOLD stage I (14% vs 10%), II
(44% vs 20%), III (34% vs 40%), and IV (8% vs 30%) be-
tween two groups (p>0.05 by Chi-square test for trend).
Lung function tests showed that he depressed COPD
patients had significantly lower FVC and %FVC than the
non-depressed patients both before and after broncho-
dilator use, although both depressed and non-depressed
COPD patients had significantly lower FEV1, %FEV1 and
FEV1/FVC both before and after bronchodilator use than
non-smokers and smokers, respectively (all p<0.001).
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FEV1 after bronchodilator use among the four groups.
Arterial blood gas analysis showed that the depressed
COPD patients (p<0.05) had significantly more severe
hypercapnia than the non-depressed patients, whereas
both depressed (both, p<0.001) and non-depressed COPD
patients (both, p<0.001) had significantly more severe hyp-
oxia than the non-smokers and smokers, respectively.
Depressed COPD patients had significantly higher
mMRC dyspnea scales (p<0.05) and lower HRQOL scores
(p<0.05) than the non-depressed patients, although both
the depressed (both, p<0.001) and non-depressed COPD
patients (both, p<0.001) had significantly higher MRC dys-
pnea scales and lower HRQOL scores than the non-
smokers and smokers, respectively.
In managements for COPD, all patients with COPD were
receiving vaccinations for seasonal and H1N1 influenza
virus and the numbers of depressed and non-depressed
COPD patients who had been receiving pneumococcal
vaccination within 5 yrs before recruitment were 13 and 8,
respectively. There was no significant difference in the ratio
of regular use of ICS, LAMA, LABA, and SRT between
non-depressed and depressed COPD patients (p=0.061,
p=0.387, p=0.601, and p=0.717, respectively. The effects of
ICS on psychological and mood status could not be di-
rectly determined, as the study was not designed to in-
clude a period for wash-out of each controller for COPD.
Plasma monoamine levels
Plasma 5-HIAA levels [median, (25% and 75% quartiles)]
in the depressed COPD patients [6.8 ng/mL, (4.9 and
13.1)] were significantly higher than in the non-depressed
patients [5.4, (4.2 and 7.5)] (p=0.022) and non-smokers
[5.1 (3.8 and 7.2)] (p=0.041), respectively, but were not
significantly higher than in the smokers [4.7, (4.0 and 6.7)]
(Figure 1).
Median (25% and 75% quartiles) plasma 5-HT levels
in the non-smokers, smokers, and non-depressed and
depressed COPD patients were 0.06 μg/mL (0.04 and
0.09), 0.05 (0.04 and 0.08), 0.06 (0.03 and 0.08), and 0.06
(0.02 and 0.09), respectively. The differences among the
four groups were not significant (Figure 1).
Median (25% and 75% quartiles) plasma HVA levels in
the non-smokers, smokers, and non-depressed and de-
pressed COPD patients were 12.8 ng/mL (11.0 and 14.8),
11.8 (10.3 and 21.3), 14.8 (11.1 and 20.9), and 15.7 (9.9
and 22.2), respectively. The differences among the four
groups were not significant (Figure 1).
Plasma MHPG level [median, (25% and 75% quartiles)]
in the depressed COPD patients [6.8 ng/mL, (5.2 and 8.7)]
(p=0.043) was significantly higher than in the smokers
[4.6, (4.3 and 5.5)]. There was no significant difference in
plasma MHPG level between the depressed COPD pa-
tients and either non-smokers [5.7 (4.7 and 7.2)] or non-depressed COPD patients [6.7, (4.1 and 8.2)] (p>0.05), re-
spectively (Figure 1).
To investigate seasonal effects in plasma 5-HIAA levels,
plasma obtained in four seasons, spring (March-May),
summer (June-August), fall (September-November), and
winter (December-February), were measured. Number of
all subjects and COPD patients in four seasons were 17
and 10, 34 and 27, 25 and 16, and 30 and 17, respectively.
There was no significant difference in median plasma 5-
HIAA [6.7 ng/mL (5.1 and 7.6) in spring, 5.3 ng/mL (4.3
and 7.4) in summer, 5.9 ng/mL (3.9 and 10.6) in fall, and
5.4 ng/mL (3.7 and 8.2) in winter, respectively, p>0.05].
The plasma levels of 5-HT, 5-HIAA, HVA, and MHPG
were not associated with age and there was no significant
difference in those plasma levels between male and female.Correlation between plasma 5-HIAA level and total CES-D
scales in patients with COPD
Plasma level of 5-HIAA (r=0.24, p=0.049), but not that of
5-HT (r=-0.06, p>0.05), HVA (r=0.19, p>0.05), or MHPG
(r=0.14, p>0.05), was significantly associated with total
CES-D scales in patients with COPD (Figure 2).Correlation between plasma 5-HIAA level and BMI, lung
function, arterial blood gas parameters, and total SGRQ
score in patients with COPD
There was a significant correlation between BMI and
plasma MHPG (r=-0.24, p=0.041), but not 5-HIAA (r=-
0.21, p>0.05), 5-HT (r=0.07, p>0.05), HVA (r=-0.09,
p>0.05), and MHPG (r=-0.24, p=0.041) level in COPD
patients.
Plasma 5-HIAA and MHPG level showed significant
negative associations with %FVC, %FEV1, and partial pres-
sure of arterial oxygen (PaO2), and positively associations
with partial pressure of arterial carbon dioxide (PaCO2)
and total SGRQ scores. There was no significant correl-
ation between the plasma 5-HT level and lung function,
arterial blood gas parameters, or total SGRQ scores.
Plasma HVA level showed a significant negative associ-
ation with %FEV1 and PaO2, and a positive association
with PaCO2 and total SGRQ scores (Table 2).Correlation between lung function, total SGRQ scores and
total CES-D scales in patients with COPD
The %FEV1 showed a significant negative association with
total SGRQ scores (r=-0.69, p<0.0001) and total CES-D
scales (r=-0.27, p=0.025) in patients with COPD. The PaO2
(r=-0.53, p<0.0001) and PaCO2 (r=0.44, p=0.0002) showed
a significant association with total SGRQ scores. Interest-
ingly, there was no correlation between PaO2 (r=-0.21,
p>0.05) and PaCO2 (r=0.22, p>0.05) and total CES-D scales
in COPD patients.
Figure 1 Plasma monoamines levels. All data are expressed as plots and boxes with median and 25% and 75% quartiles (error bars 10% to
90%). The numbers of plasma samples taken from non-smokers, smokers, and non-depressed and depressed patients with COPD were 23, 13, 50,
and 20, respectively. 5-HIAA, 5-hydroxyindoleacetic acid; 5-HT, serotonin; HVA, homovanillic acid; MHPG, 3-methoxy-4-hydroxyphenylglycol.
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To our knowledge, this is the first study to have mea-
sured the plasma levels of monoamines and their metab-
olites in depressed patients with COPD. Our present
results demonstrated that depressed patients with COPD
had significantly higher plasma 5-HIAA levels than non-
depressed COPD patients and non-smokers. The plasma
5-HIAA levels also showed a significant positive correl-
ation with the severity of depression in the patients with
COPD. Our present results support those of a previous
study demonstrating that the plasma 5-HIAA levels were
significantly increased in patients with depression rela-
tive to control subjects, and that the plasma 5-HIAA
levels were positively related to the severity of depres-
sion [14]. Previous studies have shown that the level of
5-HIAA in cerebrospinal fluid (CSF) was positively asso-
ciated with the severity of depression in abstinentalcoholics, and that treatment with the antidepressant
fluoxetine decreased both the CSF 5-HIAA levels and
the mean Hamilton depression rating scale score [27,28].
Other studies have demonstrated that decreased CSF 5-
HIAA levels were associated with attempted suicide in
patients with depression, and that non-impulsive suicide
attempters had higher plasma 5-HIAA levels than im-
pulsive suicide attempters [15,29,30]. In the COPD pa-
tients we analyzed, increased plasma 5-HIAA levels were
also associated with poor lung function, hypoxia and hy-
percapnia. Poor lung function is closely correlated with
a poor HRQOL, and may result in depression. In COPD
patients it has been shown that hypoxia and/or hyper-
capnia induces oxidative stress and results in an increase
of reactive oxygen species (ROS) throughout the whole
body including the lungs, brain, and muscles [1-5].
Therefore, it is possible that ROS may have a direct or
Figure 2 Correlations between total CES-D scales and plasma monoamines levels in patients with COPD. Correlations were analyzed
using non-parametric Spearman’s test (n=70). CES-D, Centre for Epidemiologic Studies Depression scale; 5-HIAA, 5-hydroxyindoleacetic acid; 5-HT,
serotonin; HVA, homovanillic acid; MHPG, 3-methoxy-4-hydroxyphenylglycol.
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and also affect brain serotonin turnover in the respiratory
centres/autonomic centres of the brain. Further analysis
will be needed to clarify this issue. None of the partici-
pants included in our study had previously attempted sui-
cide. It has been reported that the severity of depressionTable 2 Correlations between plasma monoamines levels and
SGRQ scores in the patients with COPD
%FVC, % %FEV1, %
5-HIAA, ng/mL −0.36 (0.002) −0.40 (<0.001)
5-HT, μg/mL −0.09 (NS) −0.08 (NS)
HVA, ng/mL −0.36 (0.002) −0.49 (<0.001)
MHPG, ng/mL −0.21 (NS) −0.46 (<0.001)
All correlation coefficients were expressed as r (p value).
Post-bronchodilator data for %FVC and %FEV1 were used.
5-HIAA, 5-hydroxyindoleacetic acid; 5-HT, 5-hydroxytryptamine; HVA, homovanillic acid
forced expiratory volume in 1 second; PaO2, partial pressure of oxygen; PaCO2, partialin patients with COPD is closely associated with suicidal
ideation [8,9]. Therefore, it would be worthwhile to rank
COPD patients in terms of current suicide risk. Taken to-
gether, the data suggest that a depressive status and the
severity of COPD may be related to increased plasma 5-
HIAA level in depressed COPD patients.lung function, arterial blood gas parameters, and total
PaO2, Torr PaCO2, Torr Total SGRQ, units
−0.38 (<0.001) 0.26 (0.031) 0.33 (0.006)
−0.17 (NS) 0.06 (NS) 0.10 (NS)
−0.39 (<0.001) 0.09 (NS) 0.26 (0.029)
−0.41 (<0.001) 0.25 (0.036) 0.40 (<0.001)
; MHPG, 3-methoxy-4-hydroxyphenylglycol; FVC, forced expiratory capacity; FEV1,
pressure of carbon dioxide; SGRQ, St. George’s Respiratory Questionnaire.
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the action of monoamine oxidase and aldehyde dehydro-
genase, resulting in the formation of 5-HIAA. In this
study, we did not find any differences in the plasma 5-HT
levels among the four groups (non-smokers, smokers,
non-depressed COPD and depressed COPD). However, a
previous study demonstrated that the plasma 5-HT levels
were increased in patients with COPD and was also asso-
ciated with aging [31]. Further analysis should be needed
to verify this issue.
HVA is a dopamine metabolite. Previous studies of pa-
tients with depression have demonstrated that the levels of
HVA in plasma and CSF decreased along with the levels of
3, 4-dihydroxyphenylacetic acid [14,32,33]. In the present
study, plasma HVA levels showed no differences among
the four groups we examined. However, the plasma level of
HVA showed significant negative associations with %FVC,
%FEV1, and PaO2 levels, and a positive association with the
total SGRQ scores in patients with COPD. In COPD pa-
tients, most of the HVA in plasma may be derived from
precursor dopamine in sympathetic nerves rather than
brain dopamine. Our results suggest that poor lung func-
tion induced ROS, and perhaps resulted in an increase of
HVA derived from precursor dopamine in sympathetic
nerves in the COPD patients we studied. Further analysis
will be needed to verify this hypothesis.
MHPG is a metabolite of both epinephrine and nor-
epinephrine. Depressed COPD patients had significantly
higher plasma MHPG levels (p=0.043) than smokers.
Placidi and coworkers [29] suggested that the level of
MHPG in CSF might have a positive correlation with ag-
gressive and impulsive suicide, and that selective norepin-
ephrine reuptake inhibitors might increase the risk of
suicidal acts. In the present study, however, the plasma level
of MHPG was not associated with the severity of depres-
sion, but showed significant negative associations with %
FEV1 and PaO2, and positive associations with PaCO2 and
the total SGRQ score in patients with COPD. Thus, the
plasma levels of both HVA and MHPG may be related to
the severity of COPD rather than to depression in COPD.
There were some limitations to the present study.
First, we measured the levels of monoamines in plasma
but not in CSF. Fluctuations in the levels of monoamines
and their metabolites can differ between peripheral
blood (plasma) and the brain (CSF). Second, the de-
pressed and non-depressed COPD patients were not
matched for the severity of COPD, and this parameter
may be correlated with plasma monoamine levels. Third,
we did not take into account the effects of treatments
with antidepressants on the plasma levels of mono-
amines in depressed COPD patients, although previous
studies have reported that antidepressants are of little
benefit to patients with COPD [9,34,35]. Further analysis
of these issues will be necessary.Conclusion
In summary, the present study has shown that plasma 5-
HIAA levels are significantly increased in COPD patients
with depression, and also associated with the severity of
depression in such patients. We also found that the
plasma 5-HIAA, MHPG, and HVA levels were negatively
associated with lung function, HRQOL and arterial
blood gas abnormalities in patients with COPD. Plasma
monoamine levels may be applicable as biomarkers for
detection of depression in patients with COPD.
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